AstraZeneca Korea Disputes Results from Latest Asthma Study

Published: 2005-04-12 06:58:00

Updated: 2005-04-12 06:58:00

AstraZeneca Korea said the results from the CONCEPT (CONtrol CEntered Patient Treatment) study, which claimed the stable-dose Seretide (salmeterol/fluticasone propionate combination) is more effective over the adjustable maintenance dose Symbicort (formoterol/budesonide), are in conflict with evi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK